AGP Executive Report
Last update: 9 hours agoCancer Drug Deal: Mankind Pharma will pay €48 million for a 70% stake in Belgian biotech Armed Cell Therapeutics, adding CAR-T programs for lymphoma and small-cell lung cancer. Obesity Treatment: Fractyl Health says its pivotal study met a six-month endpoint, with patients retaining more GLP-1-associated weight loss after stopping treatment than the sham group; longer-term results are still pending. Drug Approval Setback: Europe’s medicines committee upheld a negative opinion on Omeros’ narsoplimab for a serious transplant complication, despite the drug’s U.S. approval. Patient Data Risk: Five healthcare vendor breaches exposed data linked to nearly 36 million people, including medical and insurance details. Public Health Technology: Battelle secured a five-year, $12.3 million CDC contract to support its environmental health tracking network, plus a place on a separate support-services agreement. Digital Health Costs: Withings now charges new users $9.95 a month to sync health data with third-party apps such as Apple Health and Google Health Connect.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
Pseudo-journalism: Pink-slime
